source
- Novartis' $12 billion Avidity drug fails Phase 3 trial in myotonic dystrophyNovartis reported that its antibody-oligonucleotide conjugate del-desiran did not meet the primary endpoint in the Phase 3 HARBOR study for myotonic dystrophy type 1, showing no significant improve…
- Roivant reports record-breaking Phase 2 results for PH-ILD drug mosliciguat, starts Phase 3Roivant announced that its experimental drug mosliciguat met all primary and secondary endpoints in a Phase 2 study in patients with pulmonary hypertension associated with interstitial lung disease…